← Leaderboards
Derek C Radisky
National Jewish Health
$7,291,204
Attributed
$15,840,804
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,840,804 · 7
By mechanism
R01$15,813,398 · 6
F32$27,406 · 1
Top collaborators
- Amy C Degnim12 shared
- Mark E Sherman11 shared
- Celeste M Nelson5 shared
- Gregory Paul Downey4 shared
- Evette S Radisky4 shared
- Kathryn Jean Ruddy4 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Carl W White$29,966,481
- Gary L. Johnson$39,128,449
- Monica Kraft$36,612,836
- Dwight J Klemm$11,935,884
- Claude A Piantadosi$13,955,144
Others in their field
Top investigators on “Breast”
- David Heimbrook · Leidos Biomedical Research, Inc.$373,324,203
- Norman Wolmark · Nsabp Foundation, Inc.$299,443,204
- Carol Nesel · Westat$147,274,423
- Richard L Schilsky · University Of Chicago$122,521,723
- Walter John Curran · Thomas Jefferson University$115,541,960
- J Brooks Jackson · Social And Scientific Systems, Inc.$111,373,799
Research focus
BreastMouse ModelAffectMalignant Breast NeoplasmTissuesPublishingEpithelial CellsInnovationBenignCellsMammary Gland ParenchymaBreast DiseasesMalignant NeoplasmsBiopsyLinkWomanPathway InteractionsImmunohistochemistryBaseBreast Cancer Risk FactorCohortHigh RiskIncidenceBreast Cancer Prevention
Grant awards (31)
Proteolysis in the Pathogenesis of ARDS$683,217
R01 · FY2025 · HL
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$650,300
R01 · FY2025 · CA
Proteolysis in the Pathogenesis of ARDS$677,606
R01 · FY2024 · HL
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$637,457
R01 · FY2024 · CA
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$617,447
R01 · FY2024 · CA
Involution-based biomarkers of breast cancer risk$473,716
R01 · FY2024 · CA · contact PI
Involution-based biomarkers of breast cancer risk$141,218
R01 · FY2024 · CA · contact PI
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$890,696
R01 · FY2023 · CA
Proteolysis in the Pathogenesis of ARDS$696,074
R01 · FY2023 · HL
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$653,945
R01 · FY2023 · CA
Involution-based biomarkers of breast cancer risk$486,563
R01 · FY2023 · CA · contact PI
Involution-based biomarkers of breast cancer risk$148,650
R01 · FY2023 · CA · contact PI
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$861,161
R01 · FY2022 · CA
Proteolysis in the Pathogenesis of ARDS$728,418
R01 · FY2022 · HL
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$627,061
R01 · FY2022 · CA
Involution-based biomarkers of breast cancer risk$488,556
R01 · FY2022 · CA · contact PI
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$887,829
R01 · FY2021 · CA
Involution-based biomarkers of breast cancer risk$507,487
R01 · FY2021 · CA · contact PI
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$884,460
R01 · FY2020 · CA
Involution-based biomarkers of breast cancer risk$554,827
R01 · FY2020 · CA · contact PI
Biophysical and Biochemical Effects of the ECM on Breast Epithelial Cells$405,041
R01 · FY2019 · CA
Biophysical and Biochemical Effects of the ECM on Breast Epithelial Cells$417,569
R01 · FY2018 · CA
Biophysical and Biochemical Effects of the ECM on Breast Epithelial Cells$417,569
R01 · FY2017 · CA
Biophysical and Biochemical Effects of the ECM on Breast Epithelial Cells$417,569
R01 · FY2016 · CA
Biophysical and Biochemical Effects of the ECM on Breast Epithelial Cells$433,069
R01 · FY2015 · CA
Mechanisms of MMP-Induced Malignancy in Breast Cells$278,293
R01 · FY2011 · CA · contact PI
Mechanisms of MMP-Induced Malignancy in Breast Cells$286,900
R01 · FY2010 · CA · contact PI
Mechanisms of MMP-Induced Malignancy in Breast Cells$286,900
R01 · FY2009 · CA · contact PI
Mechanisms of MMP-Induced Malignancy in Breast Cells$286,900
R01 · FY2008 · CA · contact PI
Mechanisms of MMP-Induced Malignancy in Breast Cells$286,900
R01 · FY2007 · CA · contact PI
C/EBPbeta Affects Mammary Epithelial Cell Phenotype$27,406
F32 · FY2001 · CA